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Thérèse Huissoud, Valentin Rousson and Françoise Dubois-Arber*Abstract
Background: To determine, in a region of Switzerland, the duration of retention in opioid substitution treatments
with methadone (OSTM), duration of treatment interruptions, probability of re-entry to treatment after a treatment
interruption, and associated factors.
Methods: A secondary analysis of registry-based data was performed with patients (n = 2880) registered in the
methadone treatment register database of the Public Health Service of the canton of Vaud between January 1,
2001 and June 30, 2008. Survival analysis and multivariate analysis was conducted.
Results: The probability of remaining on treatment was 69% at 1 year and 45% at 3 years (n =1666). One-third of
patients remained on treatment beyond 5 years. The estimated hazard of leaving treatment was increased by a
ratio of 1.31 in the case of a first treatment (P = 0.001), 1.83 for those without a fixed home (P < 0.001), and 1.29 for
those younger than 30 years old (P < 0.001). The probability of having begun a new treatment after a first
interruption was 21% at one year, 38% at 3 years, and 43% at 5 years (n = 1581). Factors at the interruption of
treatment associated with a higher probability of re-entering were: interruption not due to methadone withdrawal,
bad physical health, and higher methadone dose.
Conclusions: OSTM are long-term (maintenance) treatments in Switzerland. Younger age, bad living conditions at
entry, and first treatment are predictors of lower retention. Approximately one-half of patients who interrupt
treatment will re-enter treatment within 5 years.
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Opioid substitution treatments with methadone (OSTM)
have markedly developed in Switzerland (about 7.66 mil-
lion inhabitants) increasing from approximately 5000
patients on treatment in 1989 to more than 18 000 in
2000 [1]. In 2008, more than 16 500 persons were on
OSTM in Switzerland [2], among an estimated number
of opiate-dependent persons in Switzerland of 25 000
[3]. The decrease between 2000 and 2008 is estimated
to be due to a decrease in the number of new heroin
consumers. This evolution has also occurred in other
European countries; for example, in Norway, the num-
ber of treatments rose from less than 500 in 1998 to
3000 in 2004 [4].* Correspondence: Francoise.Dubois-Arber@chuv.ch
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reproduction in any medium, provided the orFirst conceived as a therapeutic response that was li-
mited in time and ended with a withdrawal from metha-
done [5], OSTM progressively evolved towards maintenance
treatments that are considered necessary over the long-
term (methadone maintenance treatments, MMT) [6].
The current representation of drug dependence is that of
a chronic disease with repeated phases of consumption,
abstinence, and treatment [7]. Periods of abstinence are
mostly short [8,9] and are often followed by relapse [10].
In Switzerland, a therapeutic approach based on patients’
needs is currently recommended [11], and most OSTM
are probably MMT.
In the Swiss canton of Vaud (about 730 000 inhabi-
tants), the number of OSTM followed the same trend of
increase and stabilisation: since 2000, approximately
1600 patients have benefitted from an OSTM. Treat-
ments require an authorisation from the chief cantonalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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practitioners (GPs) in private practice who are allowed
to begin and regularly follow MMT. The two specialized
drug treatment centres follow only one-third of all
patients. Access to treatment is unlimited and treat-
ments are mainly oriented towards long-term MMT.
Treatments have to be in accordance with the guidelines
[12] laid down by the Cantonal Health Department
regarding treatment induction, doses, mode of delivery,
controls, security, rules for “take home” formulations,
etc. Documents of entry to treatment or prolongation of
treatment have to be filled in by the GP requiring a pre-
scription authorization (see below under methods).
Methadone in 1% solution (syrup) is the substance of
reference, but buprenorphin or – rarely - oral slow re-
lease morphine may also be prescribed, according to the
guidelines from the Swiss Society of Addiction Medicine.
These last two products are very seldom used. Medical
doctors requiring a treatment authorization from the
chief cantonal medical officer for the first time have to
engage in the continuous educational programme on
methadone. Evaluation of abstinence from drug con-
sumption is regularly conducted (e.g. with urine con-
trols). Continued drug use has to be reported to the
authority but is not a compulsory reason for removing
the patient from treatment.
Many studies have analysed treatment retention in
OSTM [4,13-20] or factors associated with retention
[21,22]. Waal’s evaluation of substitution treatments in
Norway showed a high retention rate in spite of very re-
strictive treatment rules, with less convincing results
regarding treatment outcome (rehabilitation) [4]. Accor-
ding to Magura et al. [22], factors associated with retention
are mainly related to treatment characteristics: only two of
16 pre-treatment variables, compared with five of six
during-treatment variables, had significant effects on reten-
tion. Others have analysed the periodicity of treatment(s)
and relapse(s) over time: as reviewed by Magura et al.
in 2001 [23] and Amato et al. in 2005 [24], a high rate
of relapse after the end of methadone treatment and a
rapid return to treatment have been described. In a co-
hort analysis in New South Wales, Burns et al. reported
an estimate of 197 days for treatment duration and a
mean of 2.5 treatment episodes per patient [14].
Few studies have analysed the patterns of treatment his-
tory - i.e. the occurrence of several consecutive treatment
episodes with interruptions in-between - or the duration
of treatment interruptions. In Alicante [25], a survival
analysis conducted on patients on MMT demonstrated
that 16% of patients had more than one treatment epi-
sode, with a median interruption duration of 13 months.
Patients who re-enrolled had longer total time within
MMT than patients retained in treatment and drop-outs.
This is also apparent in the study of Nosyk et al. [26].The objectives of this study are – by using registry-
based data:
 To estimate the duration of retention in MMT
(median duration and probability of staying in
treatment at different times), and the factors present
at the initiation of the treatment that are associated
with treatment duration.
 To estimate the duration of interruption, the
probability of re-entry to treatment after a first
interruption of treatment, and the factors present at
the end of the first treatment period that are
associated with re-entry.
Methods
In the canton of Vaud, methadone treatment can be
prescribed and prolongations obtained only with a
compulsory official authorization from the Chief can-
tonal medical officer, and each authorization (“entry”)
“prolongation” or “end of treatment” document is
retained in the methadone treatment register of the
canton of Vaud. The analysis includes completely anon-
ymized data of all patients registered in the methadone
treatment register database of the Public Health Service of
the canton of Vaud between January 1, 2001 and June 30,
2008. As a result, no connection to any other database
such as the death register is possible. The database
only contains a patient number for each patient; the
corresponding name is retained in the Public Health
Service of the canton of Vaud and remained unknown
to the researchers. This research received the approval
of the Chief medical officer of the canton. It is a se-
condary and retrospective analysis of anonymous data
and obtaining patient consent in this situation is not
possible.
Each patient can have three types of documents
recorded in the register under his/her patient number:
 “entry” documents, which are completed by the
doctor at each new entry to treatment, to receive
authorization from the Chief medical officer;
 “requests for a prolongation of treatment
authorization”, which are completed by the doctor
every 12 months; several requests for prolongation
may follow, year after year;
 “end of treatment” documents, which are completed
by the doctor in cases of treatment interruption and
include the reasons for interruption: true end of
treatment with methadone withdrawal or
interruption of treatment for other reasons, or
transfer to another doctor.
Each doctor following a patient on methadone must
complete these documents; data are sent to the Public
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then delivers the treatment authorization.
In case of transfer to another doctor, a relatively long
period may elapse before the new doctor sends the new
“entry” document, even if the patient continues MMT.
Because of this administrative delay up to 2 months be-
fore the registration of the new treatment document, we
have considered in this analysis a period of more than
two months to define a treatment interruption.
The following variables were included in the analysis:
age, gender, living conditions (fixed abode, without fixed
abode, or institution including prison), source of income
(full-time or part-time employment, social insurance, so-
cial aid), had a previous methadone treatment (yes/no),
currently injecting (yes/no), health (HIV test [yes/no-not
known] and HIV status [positive/negative-unknown],
HCV test [yes/no-not known] and HCV status [positive/
negative-unknown], physical condition [good/bad], psy-
chological condition [good/bad] and social situation
[good/bad], as estimated by the doctor without standar-
dized rating system), treatment administration mode
(only 2 mentions proposed without more precision:
methadone delivered each day or 1 to 4 times each
week), and methadone dose (maintenance dose). We
chose not to include the available variable “drugs use
during the treatment (heroin, cocaine/daily, occasionally,
no use during last month)” because of the bad quality of2001
time
Figure 1 Number of patients by pattern of treatment history, 2001–2
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done at the time of interruption.Statistical analysis
The duration of treatment and the duration of interrup-
tion were estimated using the Kaplan-Meier method.
Their statistical association with various factors of inter-
est was assessed using a log-rank test. P-values smaller
than 0.05 were considered statistically significant.
The data were processed using SPSS software (version
15.0) for Windows (SPSS Inc., Chicago, Illinois 60606).
The survival analysis of being in treatment was calcu-
lated from the first entry questionnaire registered after
January 1, 2001. Each patient having at least one entry
questionnaire between January 1, 2001 and June 30,
2008 was included in the analysis, (i.e., for 1666 patients;
n = 497 + 549 + 188 + 91 + 137 + 131 + 59 + 13 + 1 = 1666,
see Figure 1). For patients who had several treatment
episodes (an episode being a period of treatment without
interruption), only the first treatment episode was
included in the analysis, i.e. the unit of analysis was the
patient.2008
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pisode, beginning between January 1st, 2001, and ending after June
pisodes beginning after January 1st, 2001, ending before June 30th,
Table 1 Treatment duration and associated characteristics at entry, 2001-2008
Total N Number of
events*
Median
(days)
In treatment at
1 year %
In treatment at
3 years %
In treatment at
5 years %
P-value
All 1666 982 898 69 45 34
Had a previous treatment
Yes 1314 765 982 71 50 37 0.001
No 352 217 643 63 36 27
Sex
Male 1190 711 868 69 42 32 0.088
Female 476 271 1039 73 50 38
Age
≤30 years 700 454 718 64 41 28 < 0.001
>30 years 965 527 1037 72 50 40
Living conditions
Fixed abode 1282 715 1091 74 50 36 <0.001
Without fixed abode 160 110 377 50 27 25
Institution/Prison 189 138 434 52 27 23
Full-time job
No 1260 741 876 70 48 32 0.925
Yes 406 241 957 72 48 37
Social insurance
No 1435 858 889 68 43 33 0.093
Yes 231 124 1117 74 51 39
Social aid
No 1199 711 888 71 43 34 0.661
Yes 467 271 916 71 43 36
Good social condition
No 1241 741 868 71 43 34 0.263
Yes 425 241 1078 71 51 39
Good psychological condition
No 1239 741 888 71 43 34 0.26
Yes 427 241 960 71 47 39
Good physical condition
No 751 456 887 71 43 34 0.726
Yes 915 526 916 71 43 34
Hepatitis C status
Negative or Unknown 1132 660 909 72 46 32 0.69
Positive 534 322 869 68 44 36
HIV status
Negative or Unknown 1562 918 909 70 50 32 0.852
Positive 104 64 779 71 42 38
Currently injecting
No 1065 602 946 72 41 35 0.089
Yes 601 380 792 63 48 35
Number of methadone deliveries per week
1 to 4 454 236 1061 75 49 37 0.009
>4 1060 646 842 67 43 32
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Table 1 Treatment duration and associated characteristics at entry, 2001-2008 (Continued)
Daily methadone dosage
0.1 to 30 mg 450 260 842 68 40 29 0.407
31 to 50 mg 507 297 1057 72 48 34
51 to 75 mg 335 191 869 70 46 38
>75 mg 318 192 918 68 44 34
* An event is defined by the interruption of treatment, i.e. having an “end of treatment” document.
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ruption (i.e. having a new document of entry to treat-
ment) was calculated from the date of the first “end of
treatment” document registered for each patient. One
thousand seven hundred and eleven patients had an inter-
ruption of treatment attested by an “end of treatment”
document established between January 1, 2001 and June
30, 2008 (n = 542 + 549 + 188 + 91 + 137 + 131 + 59 + 13 +
1 = 1711, see Figure 1 which shows the distribution of the
various patterns of treatment history). However, patients
for whom the reason for the interruption of treatment was
death were excluded from the analysis (n = 130) because
they had no chance of coming back. Therefore, the prob-
ability calculation was conducted on only 1581 patients.
A multivariate analysis to test for the simultaneous asso-
ciation of various factors with the duration of treatment or
interruption was carried out using a Cox regression model.
Results
Population
Overall, 2880 different patients were registered in the
database between January 1, 2000 and June 30, 2008. For
87 patients, the documentation was insufficient to deter-
mine the evolution of treatment (only one document
was found); these patients were excluded from the ana-
lysis. For 44 patients, the dates and sequence of the va-
rious documents of “entry”, “prolongation”, and “end of
treatment” were chronologically aberrant; these patients
were also excluded.
The analysis was conducted with the remaining 2749
patients for whom several documents were available, in-
cluding one “entry” or one “end of treatment” document.
Among these 2749 patients, 541 (19.7%) had begun
treatment before January 1, 2001, had had a prolonga-
tion document for each year until 2008 and continued
their treatment without interruption until June 30, 2008
(Figure 1).
A majority of patients (57.8%) had only one treatment
episode spanning the entire period, a treatment episode
being a period of treatment without any interruption.
Among them, 497 patients had only an “entry” docu-
ment followed by several “prolongation” documents be-
cause their treatment episode was still ongoing at the
end of the study period. Similarly, 542 patients had only
an “end of treatment” document after several “prolongation”documents because during the study period, they completed
a treatment episode begun before 2001 and had not re-
entered treatment by June 30, 2008. Five hundred forty-nine
persons had a single “entry” document followed or not by
“prolongation” documents and an “end of treatment” docu-
ment recorded during the period: these individuals began
and completed a single treatment episode between 2001
and 2008.
Five hundred forty-seven patients (19.9%) had two
treatment episodes during the study period; among
them, 279 patients initially had an “end of treatment”
document, which was followed by the beginning of a
new treatment (still ongoing at June 30, 2008 for 188
individuals). Other patients (n = 268) began a treatment,
stopped it, and entered again (for 137 of these patients,
this episode was still ongoing at the end of the study
period, while 131 had finished their second treatment
episode). A small proportion of patients (2.6%) had more
than two treatment episodes: 59 persons had three, 13
persons had four, and one person began and ended treat-
ment six times during the study period.Treatment duration
The survival analysis for the first treatment episode
reveals that, of the 1666 patients registered as beginning
treatment during the study period, 982 finished this
treatment episode before June 30, 2008. Reasons for ha-
ving an “end of treatment” document included interrup-
tion (for various reasons) or the actual end of treatment
(withdrawal from methadone). The probability of remaining
on treatment was 69% at 1 year and 45% at 3 years; one-
third of patients remained on treatment beyond 5 years
(Table 1).
The duration of treatment varied with regard to a
range of factors present at treatment initiation (Table 1
and Figures 2 and 3). Variables associated with shorter
treatment duration were: participating in the first treat-
ment episode, living without a fixed abode or living in
an institution/prison, being younger than 30 years old,
and having methadone delivered 4 times a week. Metha-
done maintenance dosage reached at the beginning of
treatment, state of health as estimated by the doctor,
source of income, and gender were not associated with
treatment duration.
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Figure 2 Proportion of patients in treatment, 2001–2008 (n=1666).
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interruption of treatment (regardless of reason) came
earlier: 63% of patients undergoing the first treatment
episode remained on treatment at one year (36% at
3 years), while 71% of patients who had been in treat-
ment previously, remained on treatment at one year
(50% at 3 years) (P = 0.001). Fifty percent of patients aged
30 years and older remained on treatment after 3 years,
compared with only 40% of patients younger than 30 years
of age. It was estimated that 50% of persons living in a
fixed abode at the beginning of treatment would still be
on treatment after 3 years, compared with only 27% of0 2 4 6 8
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Figure 3 Proportion of patients in treatment with respect to treatmen
entry to treatment, 2001–2008. N at risk: first line refers to solid line; secpeople not living in such conditions (P < 0.001). For
patients living without a fixed abode, the probability of
leaving treatment was particularly high. When the doctor
reported, at the beginning of treatment, that the patient
could receive his/her methadone doses for several days,
the probability of being on treatment after 3 years was
higher (P < 0.001).
In a multivariate Cox regression model including the
four factors that were significant in the univariate ana-
lyses above, the estimated hazard of ending the treatment
was increased by a ratio of 1.31 for participants in a first
treatment (P = 0.001), by a ratio of 1.82 for those lacking a
fixed abode (P < 0.001), and by a ratio of 1.29 for patients
younger than 30 years old (P < 0.001). Having methadone
delivered each day was no longer significant (P = 0.52).
We checked for interaction between the mode of delivery
and living condition: there was no significant interaction
between these two factors (P = 0.13).
Probability of re-entering treatment after an interruption
The probability of having begun a new treatment episode,
calculated for 1581 studied patients, was 21% at one year,
38% at 3 years, and 43% at 5 years. After 5 years, the prob-
ability of re-entry became very small, with a flattening of
the survival curve of interruption (Table 2 and Figures 4
and 5). The probability of having begun a new treatment
episode differed according to the reasons for interrupting
treatment and the characteristics of the patient at the time0 2 4 6 8
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Table 2 Duration of intervals between treatment episodes and associated characteristics at treatment interruption,
2001–2008
Total N Number of
events*
Percentile
75 (days)
Out of treatment
at 1 year %
Out of treatment
at 3 years %
Out of treatment
at 5 years %
P-value
All 1581 618 478 79 62 57
Sex
Male 1118 445 455 79 62 56 0.395
Female 461 173 505 80 64 59
Age
≤30 years 591 235 432 79 63 56 0.886
>30 years 986 382 491 79 63 58
Living conditions
Fixed abode 482 178 612 82 65 58 0.996
Without fixed abode 30 12 501 87 62 57
Institution/Prison 149 53 496 78 65 60
Full-time job
No 1425 572 448 77 61 56 0.011
Yes 154 46 806 82 72 66
Social insurance
No 1460 582 466 77 62 57 0.071
Yes 119 36 547 71 72 65
Social aid
No 1377 533 474 79 63 57 0.674
Yes 202 85 496 79 59 67
Good social condition
No 1388 567 442 77 60 56 <0.001
Yes 193 51 1215 89 77 71
Good psychological condition
No 1350 547 442 77 60 54 0.003
Yes 231 71 960 84 75 64
Good physical condition
No 1205 500 433 77 60 53 <0.001
Yes 376 118 794 83 71 64
Hepatitis C status
Negative or Unknown 1316 510 488 79 63 57 0.753
Positive 263 108 445 72 60 57
HIV Status
Negative or Unknown 1530 597 484 79 62 57 0.519
Positive 49 21 395 72 60 57
Currently injecting
No 1470 572 480 79 63 57 0.767
Yes 111 46 433 79 61 57
Reason for stopping treatment
Drop-out 488 217 391 75 58 48 <0.001
Methadone withdrawal 407 125 826 85 71 63
Other reason 686 276 410 77 61 55
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Table 2 Duration of intervals between treatment episodes and associated characteristics at treatment interruption,
2001–2008 (Continued)
Daily methadone dosage
0.1 to 30 mg 548 165 945 85 73 65 <0.001
31 to 50 mg 272 124 390 77 58 48
51 to 75 mg 204 101 289 72 53 45
>75 mg 266 120 312 72 55 49
* An event is defined by re-entry to treatment, i.e.having a new document of entry to treatment.
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http://www.biomedcentral.com/1471-244X/12/238of the interruption. Among patients who had finished
their treatment and been withdrawn from methadone, the
probability of re-entering treatment after one year was
15%; among patients considered drop-outs at the moment
of interruption, this probability rose to 25% (P < 0.001).
After 3 years, it is estimated that 42% of drop-outs are
back in treatment, compared with 29% of persons ending
treatment with a withdrawal from methadone. A higher
maintenance methadone dosage at the time of interrup-
tion was significantly associated with the probability of
returning to treatment (P < 0.001).
Having a full-time job at the time of treatment inter-
ruption (P = 0.011), a good state of psychological health
(P = 0.003) or physical health (P < 0.001), and a good so-
cial situation (P < 0.001) were significantly associated
with a higher probability of not returning to treatment.
In a multivariate Cox regression model including the six
factors that were significant in the univariate analyses
above, the fact of having a full-time job was no longer sig-
nificant (P = 0.97), as were social condition (P = 0.22), xand
psychiatric condition, P = 0.42), while having a bad phy-
sical condition was just significant (P = 0.011). When ap-
plying a backward selection method, we could find a
model including three significant factors; the estimated
hazard of re-entering treatment was increased by a factor
of 1.32 if treatment had not been successful (P = 0.02), by a
ratio of 1.48 for patients in a bad physical condition (P <0 2 4 6 8
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Figure 4 Duration of intervals between treatment episodes,
2001–2008 (n = 1581).0.001), and by a factor of 1.59 if the methadone dosage
was more than 30 mg per day (P < 0.001).
Discussion
This study confirms that OSTM are actually long-term
treatments in the studied region of Switzerland. A ma-
jority of patients followed their treatment continuously:
among the patients registered between 2001 and 2008,
77.5% had only one treatment episode during the study
period, including a group (19.7% of all patients) that had
initiated treatment before the beginning of the study
period (i.e., before January 1, 2000) without any inter-
ruption until June 30, 2008, the date of the end of the
study period. Among those who started a treatment epi-
sode between January 1, 2000 and the end of the period,
69% remained in treatment after one year and 45% after
two years. The risk of interrupting treatment appeared
higher during the first 12 months of treatment.
The duration of treatment retention varies widely across
different studies. A German study [18] observed that 50%
of patients continued their treatment for more than 7 years,
with a 65% retention rate at one year. Another study in
Spain reported similar results, with a 60% retention rate at
one year and 38% at 3 years [25]. In a recent US study,
shorter treatment duration (mean 8 months) and lower re-
tention rates were observed [13]. Low retention rates at
one year (25–50% in certain studies) were reported in a
2001 review by Magura et al. [23], who identified the re-
strictive and coercive nature of specific treatment regi-
mens as factors associated with low retention rates. A
study of the treatment system in Norway [4] that demon-
strated low retention rates resulted in the loosening of
conditions of access to treatment and a modification of
exclusion rules. A recent Italian longitudinal study con-
ducted on more than 5000 patients [27] concluded that
abstinence-oriented treatments were associated with lower
retention rates than substitution-oriented treatments. A
previous study had also demonstrated poorer outcomes
with methadone reduction regimens than with methadone
maintenance regimens [20].
The high retention rate measured in the canton of
Vaud may be linked with the availability of a wide range
of substitution treatment options, from treatment with
abstinence objectives (high-threshold treatments) to
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dosage, and physical status at treatment interruption, 2001–2008. N at risk: first line refers to solid line; second line refers to dashed line.
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treatments). This high retention rate is expected to improve
patients outcomes in particular in terms of decreasing her-
oin consumption, decreasing i/v drug use and associated
risks [28].
In our study, the probability of interrupting treatment
was higher in cases of first treatment episode, in persons
without a fixed abode, and in persons younger than
30 years of age. Bell et al. already identified lower retention
rates in cases of first treatment episode [15], and lower age
has been associated with lower retention rates in several
studies [13,16,22]. Health-related variables and methadone
dose were not associated with treatment duration, al-
though methadone dose has been identified as a factor
predictive of retention [16,29]. It is likely that the metha-
done dosage reported in the entry document in our study
does not reflect the final maintenance dosage. In another
study using registry data, conducted in Ontario, Canada,
where methadone treatment may also be administered by
general practitioners, the probability to have longer treat-
ments episodes (730 days or more) was negatively asso-
ciated with the number of episodes [30].
The duration of the interruption between two treat-
ment episodes has not been studied, although it is
known that many patients experience several treatment
episodes [25,31-33]. We observed that, after a treatmentinterruption, a one-year probability of re-entering treat-
ment of 21% and a five-year probability of 43%; the
probabilities were lower when the treatment interruption
was a “true” end of treatment featuring methadone with-
drawal. After five years, the probability of re-entering
was very low regardless of the reason for interruption.
Gossop et al. [32] observed that 50% to 60% of persons
who had stopped treatment had re-entered into one or
another modality of treatment. Ball and Ross [33] esti-
mated that approximately 70% of patients who ended a
treatment with a withdrawal from methadone had either
re-entered treatment or resumed consumption of opiate
drugs of abuse.
Three factors at the interruption of treatment were asso-
ciated with a higher probability of re-entering: an interrup-
tion not due to methadone withdrawal, bad physical
health, and higher methadone dose. Bell et al. [34] demon-
strated that the significant predictors of re-entry to treat-
ment were younger age and shorter duration of the first
treatment episode.
The long treatment durations associated with high rates
of re-entry after interruption observed in our study con-
tribute additional thoughts to the debate regarding the real
possibilities of methadone withdrawal in OSTM. In light
of the known protective effects of methadone maintenance
on mortality [35,36], some professionals question the
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http://www.biomedcentral.com/1471-244X/12/238relevance of methadone withdrawal, particularly whether
it would be an inappropriate solution for many patients on
MMT [5]. In this context, Clausen et al. [36] insist on the
importance of retaining patients in treatment or rapidly re-
integrating them in cases of interruption. Strike et al. [30],
in their study of predictors of retention, suggest that repeat
episodes may not be as beneficial as previous research
reports.
In our study, the probability of re-entering was asso-
ciated with bad conditions at the time of interruption
and most cases who re-entered did so within one year,
suggesting that drop-outs have the capacity to reinte-
grate rapidly and therefore to reduce their risks (in par-
ticular linked with injection). However, a non-negligible
proportion of patients who interrupted treatment were
still out of treatment after five years, and even if we do
not know anything about their situation (particularly
regarding mortality after interruption for another cause),
it is possible that successful methadone withdrawal oc-
curred in a part of this group. However, it was not possible
to link this database with other databases, especially on
mortality. More research is still needed to assess long-
term outcomes after treatment interruption (regardless of
cause) in long-term MMT.
Our study has limitations. The first limitation is that
the analysis covers only one region of Switzerland. How-
ever, this region represents 10% of the population, and
treatment recommendations issued by the Federal Office
of Public Health are applied in the canton of Vaud.
The probability of staying in treatment was calculated
on the basis of the first “entry” document registered du-
ring the considered period. Many of these treatments
are not first treatments (the information is available) and
this overestimates the general probability of staying in
treatment since the analysis shows a lower retention for
first treatments. We nevertheless chose this option to in-
crease the number of patients in the model.
Because long delays have been observed in the admin-
istrative transmission of documents when the patient
was transferred to a different doctor [37], we considered
that when the duration of the interruption was less than
2 months, there was no treatment interruption. We may
have overestimated treatment retention and underesti-
mated the number of drop-outs by doing so. Further-
more, the register only includes patients living in the
canton of Vaud. When a person begins treatment, a pre-
vious treatment in another canton may not be men-
tioned. This would lead to a possible underestimation of
the duration of treatment.
The poor quality of data on drug use during the treat-
ment was another limitation to the analysis of the data-
base, as was the fact that the assessment of the
psychological and physical state of the patient as well as
its social inclusion was left to physician appreciationwithout standardized measurement. The quality of the
information on socio-demographic variables and other
health information (HIV/ hepatitis) was good. Overall,
we feel that these registry-based data are robust and pro-
vide useful information to health providers.
Conclusions
OSTM are long-term (maintenance) treatments in
Switzerland. Younger age, bad living conditions at entry,
and first treatment are predictors of lower retention. Ap-
proximately one-half of patients who interrupt treatment
will re-enter treatment within 5 years.
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